RhAPP
Share
Rheumatology Advanced Practice Providers 🔬
Part 2 of the EULAR ILD RhAPP Up series is now live!
In RhAPPcast: EULAR ILD RhAPP Up: Part 2, Amanda Mixon, PA-C, and Jessica Glennie, CNP, review key updates in systemic sclerosis-associated ILD and progressive pulmonary fibrosis from the 2026 EULAR Congress.
Listen now and stay tuned for Part 3: https://bit.ly/EULAR-ILD-Part2
06/17/2026
Faculty Spotlight: Bonnie Smeryage, NP🌟
RhAPP is proud to highlight Bonnie Smeryage, NP, of Joe DiMaggio Children’s Hospital in Fort Lauderdale, Florida. Thank you for your dedication to advancing rheumatology care through expertise, education, and leadership!
View her digital content here: https://loom.ly/eQzbr0A
06/16/2026
New on RhAPPcast: EULAR ILD RhAPP Up – Part 1 🫁
Join Amanda Mixon, PA-C, and Jessica Glennie, CNP, as they break down key ILD updates from the 2026 EULAR Congress. In this first episode of a special three-part series, they discuss the clinical and economic burden of CTD-ILD, the importance of early diagnosis and treatment, and emerging research that could shape the future of systemic sclerosis care.
Tune in for practical insights on evolving treatment strategies and multidisciplinary management—and stay tuned for Part 2: https://bit.ly/EULAR-ILD-Part-1
TYK2 inhibition is one of the hottest topics in rheumatology right now🔥
What do APPs need to know about the latest data in psoriatic arthritis, lupus, and Sjögren’s syndrome?
Tune in as Amanda Mixon, PA-C, Danielle Gatti-Palumbo, PharmD, and Jennifer Mylod, DNP, break down the science, clinical trials, and future of TYK2-targeted therapies.
Listen now: https://bit.ly/TYK2-Inhibition
06/11/2026
Get ready to put your rheumatology knowledge to the test with RhAPPardy! Join us for an exciting session packed with fun and challenging trivia that will keep you on your toes. Whether you're a pro or just curious, this is the perfect chance to learn and have a blast. Don’t miss out—register now and secure your spot for RhAPPardy! Let’s see who the ultimate rheumatology champ will be! 🏆
Register: https://loom.ly/AmSTbuA
06/10/2026
We're excited to spotlight Eileen Lydon, NP, of NYU Hospital for Joint Diseases!🌀
Eileen cares for patients with a wide range of autoimmune diseases, assists in evaluating hospital consults, manages outpatient rheumatology panels, and serves as a co-investigator on clinical trials. She is also passionate about educating both patients and fellow healthcare professionals on rheumatologic conditions.
View her digital education here: https://loom.ly/mb3iniA
Looking for your rheumatology community? 🩵
RhAPP Regional Meetings are more than just educational events! They're an opportunity to connect with fellow APPs, build lasting relationships, exchange ideas, and find your place within a community that understands the unique challenges and rewards of rheumatology practice.
Find a RhAPP Regional Meeting near you and become part of the RhAPP family!: https://loom.ly/rSow7Ko
Can one obesity medication deliver significantly greater weight loss than another?
Bharati Bhardwaja, PharmD, explores the SURMOUNT-5 trial, comparing tirzepatide and semaglutide in adults with obesity. Learn how tirzepatide achieved greater reductions in body weight and waist circumference, along with key safety findings that can help inform treatment decisions in clinical practice.
Watch now: https://bit.ly/SURMOUNT-5
06/04/2026
Have a clinical question? Looking for guidance from experienced rheumatology APPs?
Join RhAPP for the launch of Mentor on Demand, a new virtual interactive resource designed to connect rheumatology APPs with expert insights, practical advice, and real-world support.
Moderated by Jessica Farrell, PharmD, and Jennifer Mylod, DNP, this session is an opportunity to learn, collaborate, and engage with colleagues across the rheumatology community!
Register today: https://loom.ly/XCWOHuE
A once-daily oral therapy with no titration and no routine lab monitoring. What makes deucravacitinib different from other treatment options? 👀
Claudia Rivera-Salas, DNP, reviews the clinical profile of deucravacitinib, including its TYK2-selective mechanism of action, dosing considerations, safety profile, and its role in the treatment of psoriatic arthritis and plaque psoriasis.
Watch now: https://bit.ly/Deucravacitinib
Click here to claim your Sponsored Listing.
Category
Website
Address
Parsippany, NJ